Pluri Inc. (PLUR) AI Stock Price Forecast & Investment Analysis
Latest Analysis Date: August 22, 2025
Pluri Inc. (PLUR) - Comprehensive Stock Analysis & Investment Research
Company Overview & Business Profile
Pluri Inc. (Stock Symbol: PLUR)
is a leading company in the Life Sciences sector
, specifically operating within the Biological Products, (No Diagnostic Substances) industry.
The organization employs approximately 180 professionals worldwide
.
The company has established itself as
an emerging investment opportunity with substantial growth potential.
Financial Performance & Key Metrics Analysis
Annual Revenue: $1 million
generating a -2917.5% net profit margin
.
Market Capitalization: $-5 million - Classified as a
small-cap investment offering high growth potential.
Advanced AI Stock Prediction & Price Target Analysis
🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Pluri Inc. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.
Market Position & Competitive Advantage Analysis
Pluri Inc. strategically competes in the highly dynamic
Biological Products, (No Diagnostic Substances) marketplace,
representing an emerging small-cap investment with substantial growth potential and market disruption capabilities
.
.
Pluri Inc. Stock Price Chart and Technical Analysis
Loading chart data...
Loading Pluri Inc. interactive price chart and technical analysis...
Comprehensive Investment Metrics & Financial Analysis - Pluri Inc. (PLUR)
Deep dive into Pluri Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.
Understanding Valuation Metrics
What these metrics mean: Valuation metrics help determine if Pluri Inc. stock is fairly priced compared to its earnings, assets, and market position.
How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.
For Pluri Inc.: With a P/E ratio of -1.36, the market sees the stock as potentially undervalued.
P/E Ratio-1.36x
P/B Ratio-9.10x
Market Cap$-5M
EPS$-3.63
Book Value/Share$-0.58
Revenue/Share$-1.23
Understanding Profitability Metrics
What these metrics mean: These ratios measure how efficiently Pluri Inc. converts revenue into profit and generates returns for shareholders.
How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.
For Pluri Inc.:
Operating Margin-2813.0%
Net Margin-2917.5%
Understanding Financial Health Metrics
What these metrics mean: These ratios assess Pluri Inc.'s ability to meet short-term obligations and manage debt levels effectively.
How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.
For Pluri Inc.:
Understanding Cash Flow Metrics
What these metrics mean: Cash flow metrics reveal Pluri Inc.'s ability to generate cash from operations and fund growth initiatives.
How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.
For Pluri Inc.:
Understanding Operational Efficiency Metrics
What these metrics mean: These ratios measure how effectively Pluri Inc. uses its assets and manages working capital.
How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.
For Pluri Inc.:
Understanding Financial Statement Data
What these metrics mean: Key figures from Pluri Inc.'s income statement and balance sheet showing absolute financial performance.
How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.
For Pluri Inc.: With annual revenue of $1M, Pluri Inc. represents a smaller but potentially high-growth operation.
Income Statement ($ Millions)
Total Revenue$1M
Operating Income$-17M
Net Income$-17M
R&D Expense$11M
Cost of Goods Sold$-5M
Balance Sheet Highlights ($ Millions)
Dividend & Shareholder Information
Shares Outstanding-1M
Growth Metrics (YoY)
EPS Growth-101.7%
Pluri Inc. (PLUR) Fundamental Analysis & Insider Trading Data
(Quarterly Financial Reports)
Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Pluri Inc. stock analysis.
Loading fundamental data...
Loading Pluri Inc. comprehensive fundamental analysis and insider trading data...
Latest Pluri Inc. Stock News & Market Analysis
Breaking news, analyst reports, and market updates affecting Pluri Inc. (PLUR) stock price and investment outlook.
--Pluri Inc., a leading biotech company that transforms cells into solutions that promote wellbeing and sustainability, today unveiled a breakthrough in cell manufacturing that potentially solves ...
HAIFA, Israel, May 20, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), which transforms cells into solutions that ...
For example, Pluri is using forward-looking statements when it discusses its belief that its patent represents a major breakthrough in Pluri's proprietary 3D bioreactor technology, the potential ...
--Pluri Inc., a leading biotechnology company that transforms cells into solutions, today announced that a reverse share split of the Company’ s issued and outstanding common shares, par value ...
HAIFA, Israel, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”) (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology ...
Pluri Inc, formerly Pluristem Therapeutics, is a biotechnology research company developing medical, pharma, and food products from placenta-based stem cells R&D. Pluri's bitty revenue over decades ...
HAIFA, Israel, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that ...
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it has entered into a Memorandum of Understanding ...
(RTTNews) - Pluri Inc. (PLUR), Monday announced it has completed the strategic acquisition of a 71 percent equity stake in Kokomodo Ltd., a cultivated cacao AgFoodTech company, for $4.5 million in ...
HAIFA, Israel, April 27, 2023 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that ...
Patent helps position Pluri as a leader in cell expansion for the agtech industry with the launch of its PluriAgtech business vertical and cell-based coffee productHAIFA, Israel, March 11, 2024 ...
Pluri Inc. Competitors & Peer Analysis - Life Sciences Sector
Comparative analysis of Pluri Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.
Frequently Asked Questions - Pluri Inc. Stock Forecast
How accurate are Pluri Inc. stock predictions?
Our AI model demonstrates 27% historical accuracy for PLUR predictions, based on advanced machine learning algorithms trained on over 10 years of market data.
What factors influence Pluri Inc. stock price forecasts?
Based on our AI analysis, Pluri Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.
How often are Pluri Inc. forecasts updated?
Pluri Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.
Want More Advanced Pluri Inc. Analysis?
Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Pluri Inc. stock.
